Immutep Limited (NASDAQ:IMMP) Short Interest Up 6.6% in June

Immutep Limited (NASDAQ:IMMP) was the target of a large increase in short interest during the month of June. As of June 15th, there was short interest totalling 4,180,000 shares, an increase of 6.6% from the May 31st total of 3,920,000 shares. Based on an average daily trading volume, of 247,200 shares, the short-interest ratio is presently 16.9 days.

Institutional Investors Weigh In On Immutep

Several hedge funds and other institutional investors have recently added to or reduced their stakes in IMMP. BNP Paribas Financial Markets boosted its position in shares of Immutep by 15.4% in the first quarter. BNP Paribas Financial Markets now owns 35,300 shares of the biotechnology company’s stock worth $82,000 after purchasing an additional 4,700 shares during the period. Virtu Financial LLC increased its stake in Immutep by 269.4% in the 1st quarter. Virtu Financial LLC now owns 45,062 shares of the biotechnology company’s stock worth $105,000 after buying an additional 32,864 shares in the last quarter. PFG Investments LLC bought a new stake in Immutep during the first quarter valued at about $119,000. Meridian Wealth Management LLC lifted its position in shares of Immutep by 3.6% in the fourth quarter. Meridian Wealth Management LLC now owns 322,450 shares of the biotechnology company’s stock valued at $774,000 after acquiring an additional 11,250 shares in the last quarter. Finally, Oracle Investment Management Inc. grew its position in shares of Immutep by 9.4% during the first quarter. Oracle Investment Management Inc. now owns 564,879 shares of the biotechnology company’s stock worth $1,316,000 after purchasing an additional 48,449 shares in the last quarter. 2.32% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on IMMP. Capital One Financial assumed coverage on Immutep in a research note on Friday, May 17th. They issued an “overweight” rating and a $10.00 price target on the stock. Robert W. Baird dropped their price objective on shares of Immutep from $7.00 to $6.00 and set an “outperform” rating on the stock in a report on Thursday, June 27th.

Immutep Stock Down 6.5 %

NASDAQ IMMP opened at $1.88 on Wednesday. Immutep has a 52 week low of $1.58 and a 52 week high of $3.34. The stock’s 50-day moving average price is $2.73 and its 200-day moving average price is $2.51.

About Immutep

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system.